Introduction
Thyroid nodules are common and can be discovered by clinical palpation in 5% of normal individuals and by highresolution ultrasonography (USG) in 60% of the general population [1, 2] . Although most nodules are benign and do not grow, some nodules do become large and symptomatic [1, 2] . Some patients may experience pain in the neck, jaw or ear and cosmetic unsightliness that adversely impacts appearance and social functioning. If left untreated, some patients may even experience difficulty with breathing and swallowing and hoarseness of voice leading to impaired physical and mental health-related quality of life (HR-QOL).
Patients' HR-QOL is not only affected by thyroid nodules themselves, but also by the subsequent treatments. There are essentially three therapeutic options for symptomatic benign thyroid nodules [3] . First is close surveillance with lifetime regular follow-ups. Although it is the least costly option, more costly treatments may follow if the disease progresses. Second is surgical resection or surgery. This is a 'one-off' treatment, is associated with a high initial cost, and patients may still need regular visits to check on their thyroid function afterwards. Third is a nonsurgical minimally invasive option which includes any form of thermal ablative therapies or ethanol injection. This third option is a 'one-off' treatment in most instances but it has the highest initial cost of the three options and regular follow-up visits are necessary. A recent longitudinal study on 40 patients with symptomatic nodules [4] reported that after a 2-year period, the thermal ablation was associated with physical and mental aspects of HR-QOL improvements, possibly due to the reduction in compressive and cosmetic symptoms [5] . Based on a recent study [6] , the non-surgical, minimally invasive option may lead to greater improvement in HR-QOL compared with surgery, but is unlikely to be cost effective over time at its current price. Besides treatment issues, patients enrolled in the conservative management or close monitoring strategy may have additional uncertainty, anxiety, and worries about the development of thyroid cancer. Often, the costeffectiveness analysis of health interventions requires the input of a health utility score, a composite preferenceweight of HR-QOL theoretically ranging from zero for death to one for full health. Although there is no general recommendation for a reference case and preferable health utility measure for economic evaluations in Hong Kong, a valid and reliable utility instrument is desirable to influence decision making and cost-effectiveness analysis of treatment options for symptomatic benign thyroid nodules.
Therefore, measurement of HR-QOL and utility scores are important in the subjective outcome and health economic evaluation of management for patients with symptomatic benign thyroid nodules. Indeed, to our knowledge, there are currently no disease-specific HR-QOL instruments specifically designed for symptomatic benign nodular goitre, suggesting the use of existing generic HR-QOL and utility score instruments might be acceptable. Although one previous study [6] estimated utility scores of patients with thyroid nodules through the EuroQoL Five-Dimension (EQ-5D) instrument, the psychometric properties of the commonly used utility instruments EQ-5D and SF-6D (Short-Form Six-Dimension) and their pairwise comparisons in patients with symptomatic benign thyroid nodules were not determined. Therefore, the present study aimed to assess the acceptability, validity, and reliability of the EQ-5D and SF-6D instruments in patients with symptomatic benign thyroid nodules by doing a head-to-head comparison of psychometric properties among instruments.
Methods and Patients

Study Design and Patients
This was an interim analysis of data collected from an ongoing prospective trial (already approved by the local institutional review board and registered with http://www. clinicalTrials.gov (NCT02398721). Over a 9-month period, consecutive patients presenting for the first time with a thyroid swelling were evaluated. To be eligible, first the thyroid swelling had to be benign (i.e., Bethesda class II on fine needle aspiration cytology [FNAC] within 3 months of recruitment and a low or very low suspicion sonographic pattern on USG). Second, the swelling (which could either be a solitary nodule or a dominant nodule in a multinodular gland) had to be causing obstructive or pressure symptoms. A swelling simply causing non-specific neck complaints or cosmetic concern was not included. Third, the index nodule had to have all three orthogonal dimensions C10 mm on USG. Also, patients with severe existing medical co-morbidities or terminal malignancy were not eligible. Patients with previous history of thyroid surgery, or indeterminate, suspicious of malignancy, or malignant FNAC (i.e. Bethesda class III or above) were excluded from the current analysis.
After informed consent, eligible patients were interviewed and were asked to fill in a structured HR-QOL questionnaire consisting of the traditional Chinese (Hong Kong) version of SF-12 Health Survey version 2, SF-6D, EQ-5D 5-level (EQ-5D-5L), and questions on socio-demographics. As for consistency in administration modes, all questionnaires were administered by an interviewer because elderly patients with low literacy levels were incompetent to self-complete questionnaires. The SF-12v2, SF-6D, and EQ-5D-5L questionnaires were administered at baseline, and then the three questionnaires and a global rating of change scale were administered at 2 weeks after baseline to assess test-retest reliability.
Study Instruments
EuroQoL Five-Dimension Five-Level (EQ-5D-5L)
The EQ-5D-5L is a generic preference-based measure developed by the EuroQol Group for measurement of HR-QOL, providing descriptions of five dimensions of health status. The EQ-5D-5L has five domain scales (mobility, self-care, usual activities, pain and discomfort, and anxiety and depression) and five levels for each domain. Since the Chinese-specific EQ-5D-5L value set/tariff is currently not available, we applied a two-step indirect approach to estimate EQ-5D-5L scores applicable for the Chinese population, as adopted in previous studies [7] [8] [9] . The first step was the application of an indirect interim mapping method [10] . The EQ-5D-5L health status was transformed to EQ-5D-3L health status according to the transition probability matrix. Finally, EQ-5D-3L health status was scored according to a recently developed Chinese-specific EQ-5D-3L value set [11] , ranging from -0.149 for the worst health status (33333) to 1 for the full health status (11111). A higher score in EQ-5D-5L indicated better HR-QOL.
Short-Form 12-Item Health Survey (SF-12)
The Chinese (Hong Kong) SF-12v2 has been validated and normed on the general Chinese population in Hong Kong. It measures eight domains of HR-QOL on physical functioning (PF), role physical (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role emotional (RE), and mental health (MH) on a scale with a theoretical range from 0 to 100. A higher score indicates better HR-QOL. The eight domain scores were aggregated based on population-specific weights to calculate two summary scores, the physical (PCS) and mental component summary (MCS) scores.
Short-Form 6-Dimension (SF-6D)
In this study, the SF-6D utility score was directly converted from raw responses from the SF-6D instrument. Specifically, estimation of SF-6D utility score is possible with the available item responses of either SF-6D or SF-12v2 [12] instrument. Previous research show that SF-6D utility score measured by SF-6D instrument was more sensitive and preferable than that derived from the SF-12v2 instrument [13] . The Hong Kong SF-6D value set [14, 15] was derived by standard gamble valuation method [12] . The theoretical range of SF-6D utility score ranged from 1 for full health to 0.315 for the worse possible health state according to a Chinese Hong Kong population-specific scoring algorithm [14, 15] . The SF-6D utility score serves as preference weighting input to quality-adjusted life-year outcomes in economic evaluation.
Global Rating of Change Scale
The global rating of change scale is a single item: ''Compared to the first visit, how would you rate your overall health now?'' with a 7-point Likert scale rating from 'extremely worse' (rating of -3) to 'extremely better' (rating of ?3) health condition compared with the previous assessment at baseline. It has been widely used as an external criterion of change in heath condition [16, 17] . Patients who self-rated '0' as an indication of 'stable' in health condition change were selected for test-retest reliability assessment.
Statistical Analysis
Descriptive statistics including mean, standard deviation (SD), and percentage of floor and ceiling effects of each subscale and each summary scale were calculated.
The acceptability of instruments [18] was assessed using the proportion of missing values, and proportion of patients giving the highest possible and lowest possible responses, denoted as ceiling effect and floor effect. At least 15% of subjects achieving the lowest or highest possible score was considered as the presence of floor or ceiling effect, respectively. Based on patients with stable health condition over a 2-week duration, 2-week test-retest reliability was assessed by intra-class correlation (ICC) coefficient using a value C0.7 to indicate adequate reproducibility. A weighted Kappa [19] The construct validity [20] of the SF-6D and EQ-5D-5L utility scores was assessed using a correlation test against the SF-12v2 subscale scores holding similar constructs. Concerning the possible violation of normality assumption for HR-QOL and health utility scores, Spearman's rank correlation test was used. We hypothesized that the utility scores were moderately correlated with SF-12v2 summary scores, since those scores were composite scores of different important HR-QOL domain scores. Data analyses were conducted using SPSS Windows 23.0 (IBM SPSS Inc., Chicago, IL, USA). A p value \0.05 was statistically significant.
Results
Baseline Patient Characteristics
A total of 314 patients were enrolled and of these, 20 patients (6.5%) with previous history of thyroid surgery were excluded. Therefore, a total of 294 patients were included for analysis. Table 1 shows the characteristics of patients included in this study. The male:female ratio was 1:6.4. The mean (±SD) age at presentation was 56.59 ± 11.67 years. The mean body mass index was 23.33 ± 3.29 kg/m 2 . All participants were euthyroid on presentation. The mean serum thyroid-stimulating hormone (TSH) level was 1.33 ± 0.99 mIU/L (normal 0.05-4.2 mIU/L). The majority (n = 225, 71.7%) had multiple benign-looking nodules in their gland (i.e., multinodular goitre). The mean size of the dominant (largest) nodule was 2.4 ± 2.3 cm (range 1.6-3.8). Figure 1 plots the response distributions related to all dimensions of both the EQ-5D-5L and SF-6D instruments. Table 2 entails the descriptive statistics of health utility scores and detailed response distributions of the EQ-5D-5L and SF-6D domains. The highest proportion of 'no problems' response referred to the social functioning domain in SF-6D and the self-care domain in EQ-5D-5L. The mean EQ-5D-5L and SF-6D utility scores were 0.901 ± 0.113 and 0.773 ± 0.139, respectively, where distribution of EQ-5D-5L was heavily left-skewed. A ceiling effect was observed for EQ-5D-5L. No significant ([15%) floor and ceiling effects were observed for the SF-6D utility score. Table 3 depicts the 2-week test-retest reliability among HR-QOL and utility instruments. For 2-week test-retest assessment, 130 patients completed the full set of HR-QOL questionnaires. The mean follow-up duration was 17.1 days, with a range of 9-51 days. Based on an external criterion indicating change in health status compared with baseline assessment, 104 patients perceived their health condition to be stable over the 2-week duration, a retest time frame that is commonly adopted for test-retest reliability [21] . The SF-6D utility scores showed good test- BMI body mass index, FT4 free thyroxine, RAI radioactive ablation iodine, SD standard deviation, TSH thyroid-stimulating hormone retest reliability (0.794; range 0.696-0.860), but ICC of the EQ-5D-5L score was \0.7. Weighted kappa, indicating agreement between two assessments, was interpreted as fair-moderate (0.223-0.445) for six dimensions of SF-6D, and poormoderate (0.149-0.344) for five dimensions of EQ-5D-5L. Better reliability was observed in the SF-6D utility score than in the EQ-5D utility score.
The SF-6D utility score had a moderate-strong Spearman rank correlation with SF-12v2 domain and summary scores (0.461-0.630) that conceptually measures the similar constructs, providing evidence for adequate construct validity (Table 4) . Only fair-to-moderate Spearman rank correlations between EQ-5D-5L score (0.310-0.552), and SF-12v2 domain scores were observed. In particular, Spearman correlations between EQ-5D-5L score and SF12v2 summary scores were fair to moderate (0.257-0.457).
Discussion
This psychometric validation study is the first report to evaluate acceptability, reliability, and validity of HR-QOL and utility instruments in patients with symptomatic benign thyroid nodules. In evaluating acceptability, about half of patients self-reported the EQ-5D-5L health profile of '11111', suggesting an observed ceiling effect for the EQ-5D-5L score. As such, the EQ-5D-5L score may reflect the better health status condition of symptomatic benign thyroid nodules and the lack of room for improvement in health utility score as a result of clinical interventions. There were no observed floor and ceiling effects for the SF-6D score, demonstrating substantial acceptability of the two instruments. The reliability of instruments is an essential psychometric property of HR-QOL and utility assessment. It refers to the ability to reproduce consistent responses within a short period of time. The test-retest reliability of the SF-6D score was satisfactory, whereas the EQ-5D-5L score had inadequate reproducibility. The response test-retest reliability measured by weighted kappa was fair to moderate for SF-6D dimensions but poor to moderate for EQ-5D-5L dimensions, in line with the testretest reliability of their utility scores. The reliability of the SF-6D instrument was superior to that of the EQ-5D-5L instrument for symptomatic benign thyroid nodules. To ascertain the construct validity of HR-QOL and utility instruments, the generic SF-12v2 instrument was used as an anchor assessing whether dimensions of SF-12v2 hold Fig. 1 Response distribution of domains in SF-6D instrument (upper) and EQ-5D-5L instrument (lower) good correlation with dimensions in other instruments with similar construct. Correlation between SF-12v2 dimension scores and utility scores reflected the significant strength of SF-6D over EQ-5D-5L. All subscale and summary scores of SF-12v2 were more correlated with SF-6D score than EQ-5D-5L score, in part due to the fact that items in the SF-6D were extracted from the SF-12 instrument. Moreover, the SF-6D score had moderate correlation to the PCS (r = 0.630) and MCS (r = 0.461) scores of SF-12v2, but a weak correlation (r = 0.257) between the EQ-5D-5L score and MCS score of SF-12v2 was observed.
One possible explanation for the differences in psychometric properties between SF-6D and EQ-5D-5L utility scores was in part due to the differential scoring algorithms available for use in Hong Kong general and patient populations. Performance of acceptability and psychometric properties may be influenced by the scoring algorithms used for conversion. Unlike the direct approach used for calculation of the SF-6D score, the EQ-5D-5L utility score was derived via a two-step indirect approach: an interim mapping algorithm plus an EQ-5D-5L value set derived from mainland China, neither of which were based on the Hong Kong Chinese population. Moderate correlation (r = 0.556) between two utility scores reflected the reality that concepts in one utility score were not perfectly cap- tured by another utility score, and thus echoed the importance of utility instrument selection. The impact of utility score selection, referring to SF-6D score versus EQ-5D-5L score, on quality-adjusted life-years, incremental cost-effectiveness ratio, and decision making of clinical interventions for thyroid nodules needs further exploration.
Limitations
Firstly, the four instruments used in the current study may not be the best available HR-QOL and utility instruments designed for symptomatic benign thyroid nodules. A recent systematic review [22] appraising the quality of 14 standardized instruments recommended the use of the ThyPRO instrument, initially developed by a Danish research group, for HR-QOL assessment in patients with benign thyroid diseases. The cross-cultural validity of ThyPRO has been assessed at multiple clinical sites in multiple countries [23] . However, a simplified or traditional Chinese version has not been validated and was unavailable at the time of study. Future work on the psychometric properties of the ThyPRO instrument or other existing HR-QOL instruments specific to symptomatic benign thyroid nodules are warranted to enable the subjective evaluation of clinical interventions over time as well as integration of HR-QOL measurement into routine care of thyroid nodules. Secondly, unlike psychometric testing on instruments used for moderate and severe disease, HR-QOL scores in symptomatic benign thyroid nodules were not hypothesized to have significant correlation with any clinical characteristics such as size of nodules, number of nodules, and treatment modalities. Therefore, no analysis was conducted to assess correlations between HR-QOL and clinical characteristics.
Thirdly, the SF-12v2 scores were in principle more correlated with SF-6D scores than other scores, given the fact that SF-6D is the abbreviated form of SF-12v2. There was a possibility of favoring SF-6D in the evaluation of construct validity. In the current study, The SF-6D score was not calculated from seven item responses from the SF-12v2 instrument (i.e., SF-12-derived SF-6D score). Both the SF-6D and the SF-12v2 instruments were separately administered to each patient, gathering a different set of responses from the two instruments. The SF-12 was assumed to be the 'gold standard' of HR-QOL measurement testing against other HR-QOL and utility scores. Nevertheless, this is presumably the best 'gold standard' among the four instruments because this generic instrument has been validated in the Hong Kong general population [24] . Since instruments were not administered in a randomized order, there was also the possibility of context effect (or 'order effect') on HR-QOL and utility measurement.
Fourthly, this study was the secondary analyses of data collected within a randomized controlled trial design. Since the trial was not designed for the purpose of psychometric evaluation, this paper lacks important information for a comprehensive acceptability investigation such as time for instrument completion, and patients' perceived views and feedback on each instrument.
Finally, the patients were sampled from the endocrinology and surgical outpatient clinic of one hospital in Hong Kong and so our findings might be less generalizable to non-Chinese populations.
Conclusions
The SF-6D instrument demonstrated satisfactory acceptability and psychometric properties in patients with symptomatic benign thyroid nodules, whilst the EQ-5D-5L instrument was less reproducible than the SF-6D instrument at the test-retest assessment. These findings support the use of the SF-6D instrument to evaluate HR-QOL in routine care as well as the adoption of its utility score in the health economic evaluation of patients with symptomatic benign thyroid nodules.
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